JNJ Price Soars, But Our DCF Analysis Says It's Overvalued by 122%

Johnson & Johnson (JNJ) has seen significant price growth recently, but our DCF analysis suggests that it may be overvalued.

The company's year-to-date increase is 35.1%, and its one-year rise is 57.7%. However, our valuation models indicate a different story regarding its current valuation.

Our DCF earnings-based model estimates the intrinsic value of JNJ at $123.97, compared to its current price of $275.23. This represents a margin of safety of -122.0%.

The Free Cash Flow (FCF) DCF model also indicates that JNJ is significantly overvalued, with an intrinsic value of $105.26 and a margin of safety of -161.5%.